NEW YORK (GenomeWeb) – Biosensor firm Silicon Kinetics said today it is collaborating with Biosys Technologies, Tokyo University, and St. Marianna University School of Medicine in Japan on a screening project for lung cancer drugs.

Under the terms of the collaboration, the parties will use Silicon Kinetics' Molecular Interaction Kinetics-Mass Spectrometry (MIK-MS) technology to screen and rank inhibitors targeting lung cancer as part of a larger study investigating the progression of lung cancer in non-smoking adults, along with potential personalized treatments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.